Johnson & Johnson must pay $257.6 million to the state of Louisiana for making misleading claims about the safety of the company’s Risperdal antipsychotic drug, a jury concluded.
To contact the reporter on this story: Jef Feeley in Wilmington at jfeeley@bloomberg.net
To contact the editor responsible for this story: Peter Blumberg at pblumberg1@bloomberg.net
via bloomberg.com
No comments:
Post a Comment